Noile-Immune Biotech

company

About

Noile-Immune Biotech is a national cancer research center specializing in the development of cancer immunotherapies.

  • 11 - 50

Details

Last Funding Type
Corporate Round
Last Funding Money Raised
¥1B
Industries
Biotechnology
Founded date
Apr 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University.
They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
¥3.44B
Noile-Immune Biotech has raised a total of ¥3.44B in funding over 2 rounds. Their latest funding was raised on Mar 22, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 22, 2021 Series C ¥2.38B 2 BiGEN Detail
May 31, 2018 Series Unknown ¥60M 2 Detail
Sep 4, 2017 Corporate Round ¥1B 1 Takeda Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Noile-Immune Biotech is funded by 4 investors. BiGEN and Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
BiGEN Yes Series C
Takeda Yes Corporate Round
Healthcare Innovation Series C
SAIKYO Series Unknown